Please assess the completion status of the following clinical trial:

Trial Title: The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients undergoing coronary angiography+/-Percutaneous Coronary Intervention (PCI) for NSTE-ACS~2. Requirement for CIN prophylaxis as per Barts Heart Centre Criteria for CIN prophylaxis:~   eGFR\<60ml/min OR 2 of the following: diabetes, liver failure (cirrhosis), age \> 70yr, exposure to contrast in last 7 days, heart failure (or LVEF\<40%), concomitant renally active drugs (ACEi, ARB, NSAIDs, aminoglycosides, diuretics)~3. Aged \>18~4. Patients able and willing to give their written informed consent.~Exclusion Criteria:~1. ST segment myocardial infarction undergoing Primary PCI.~2. Patients with eGFR\<30ml/min or on renal replacement therapy~3. Subjects presenting with cardiogenic shock (systolic blood pressure \<80 mmHg for \>30 minutes, or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation~4. Current life-threatening condition other than vascular disease that may prevent a subject completing the study.~5. Use of an investigational device or investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication.~6. Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures).~7. Severe acute infection~8. Pregnancy~9. Breast-feeding mothers.~10. Any Inclusion Criteria not met

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Potassium Nitrate (Type: ACTIVE_COMPARATOR): Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
- Potassium Chloride (Type: PLACEBO_COMPARATOR): Potassium Chloride

Based on this trial design, predict the completion outcome and termination type (if applicable).